Filing Details
- Accession Number:
- 0001209191-23-042566
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-07-18 16:17:01
- Reporting Period:
- 2023-07-14
- Accepted Time:
- 2023-07-18 16:17:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1197036 | I Bruce Sachs | C/O Vertex Pharmaceuticals Incorporated 50 Northern Ave Boston MA 02210 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-07-17 | 11,250 | $127.54 | 51,250 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-07-17 | 1,697 | $355.54 | 49,553 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-07-17 | 5,711 | $356.75 | 43,842 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-07-17 | 3,842 | $357.29 | 40,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Deferred Stock Units | Acquisiton | 2023-07-14 | 125 | $350.79 | 125 | $0.00 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-07-17 | 11,250 | $0.00 | 11,250 | $127.54 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 14,525 | No | 4 | A | Direct | ||
| 11,250 | 2025-05-31 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.
- Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $355.54 (range $355.00 to $355.97).
- Open market sales reported on this line occurred at a weighted average price of $356.75 (range $356.00 to $356.99).
- Open market sales reported on this line occurred at a weighted average price of $357.29 (range $357.00 to $357.38).
- Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.
- Fully vested.
Billionaire Hedge Funds
